Ignite Creation Date:
2024-05-06 @ 2:15 PM
Last Modification Date:
2024-10-26 @ 1:28 PM
Study NCT ID:
NCT04265937
Status:
RECRUITING
Last Update Posted:
2023-05-31
First Post:
2020-02-08
Brief Title:
ScreenIng of Genetic Susceptibility Genes for Breast Cancer Patients in CHinese communiTies
Sponsor:
Fudan University
Organization:
Fudan University
Study Overview
Official Title:
Screening of Genetic Susceptibility Genes for Breast Cancer Patients and Establishment of High-risk Populations in Chinese Communities
Status:
RECRUITING
Status Verified Date:
2023-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
SIGHT
Brief Summary:
This is a community-based prospective study and the research object is breast cancer patients It is planned to take the community as the unit to inform and collect the breast cancer patients who voluntarily participate to carry out the detection of BRCA1 BRCA2 PTEN CHEK2 and PALB2 genes through the community health service center
Detailed Description:
This is a population-based prospective cohort study which has been ongoing in 3 provinces of eastern China since 2019 Up to 5000 breast cancer survivors will conduct BRCA1 BRCA2 PTEN CHEK2 and PALB2 genetic susceptibility genes testing fill in clinical and genetic information forms and collect family history Mutation rate of BRCA12 and other genetic susceptibility genes in Chinese community breast cancer population will be measured Logistic regression will be performed to establish a prediction model for the probability of BRCA12 and other gene mutations Kin-Cohort method will be used to calculate the penetrance of breast cancer and other common malignancies in BRCA12 and other genetic mutation carriers
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None